Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS)

Russo, Francesco Paolo; Izzy, Manhal; Rammohan, Ashwin; Kirchner, Varvara A.; Maira, Tommaso Di; Belli, Luca; Berg, Thomas; Berenguer, Marina; Polak, Wojciech

doi:10.1016/j.jhep.2021.09.041

Cited by 24 publications

(41 citation statements)

References 32 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the USA, suspension of live donor transplantation were 68% in March 2020, while restrictions/suspension of deceased donor transplantation reached 73% 87. Despite a low response rate (about 23%), data from a web-based survey, including three global areas (North, Central and South America, Europe and the rest of the world), showed significant differences in the number of candidates on the waiting list between the early pandemic and the pre-pandemic periods, as well as the number of LTs performed 88. These trends from the early phase likely reflected caution about the safety of LT recipients and a reallocation of human and instrumental resources dedicated to COVID-19 healthcare.…”

Section: Covid-19 and Liver Transplantmentioning

confidence: 99%

COVID-19 and liver disease

Dufour

Marjot

Becchetti

et al. 2022

Gut

View full text Add to dashboard Cite

Knowledge on SARS-CoV-2 infection and its resultant COVID-19 in liver diseases has rapidly increased during the pandemic. Hereby, we review COVID-19 liver manifestations and pathophysiological aspects related to SARS-CoV-2 infection in patients without liver disease as well as the impact of COVID-19 in patients with chronic liver disease (CLD), particularly cirrhosis and liver transplantation (LT). SARS-CoV-2 infection has been associated with overt proinflammatory cytokine profile, which probably contributes substantially to the observed early and late liver abnormalities. CLD, particularly decompensated cirrhosis, should be regarded as a risk factor for severe COVID-19 and death. LT was impacted during the pandemic, mainly due to concerns regarding donation and infection in recipients. However, LT did not represent a risk factor per se of worse outcome. Even though scarce, data regarding COVID-19 specific therapy in special populations such as LT recipients seem promising. COVID-19 vaccine-induced immunity seems impaired in CLD and LT recipients, advocating for a revised schedule of vaccine administration in this population.

show abstract

Section: Covid-19 and Liver Transplantmentioning

confidence: 99%

COVID-19 and liver disease

Dufour

Marjot

Becchetti

et al. 2022

Gut

View full text Add to dashboard Cite

show abstract

“…[ 1 ] Reduction of immunosuppression is therefore not routinely recommended but needs to be made on a case‐by‐case basis, especially in patients admitted to the intensive care unit (ICU). [ 5 ] Our patients received the standard immunosuppression, and no difference in the rates of rejection were noted between the COVID‐19 and pre–COVID‐19–LT groups (Table 2 ).…”

Section: Tablementioning

confidence: 95%

“…As a result of SARS‐CoV‐2 infectivity, transplant societies recommend a “cooling‐off period” after pulmonary symptom resolution. [ 3 , 5 ] However, patients with a Model for End‐Stage Liver Disease (MELD) score greater than 15 remain at high risk of liver failure and early death, making a stringent application of this cooling‐off period impracticable. Nevertheless, the risk of mortality without LT in these patients needs to be balanced against the risk of post‐LT mortality.…”

Section: Tablementioning

confidence: 99%

Outcomes of liver transplantation in recipients with previous coronavirus disease 2019 infection

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Analysis of 128 surveys completed by transplant centers from all over the world revealed a decrease in the number of performed liver transplants and wait-listed candidates with higher mortality among this group in comparison to 2019 [41].…”

Section: Sars-cov-2 Infection and Liver Transplantationmentioning

confidence: 96%

Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)—A Narrative Review

Łykowska‐Szuber

Wołodźko

Rychter

et al. 2021

JCM

View full text Add to dashboard Cite

While respiratory symptoms are prevalent in SARS-CoV-2 infected patients, growing evidence indicates that COVID-19 affects a wide variety of organs. Coronaviruses affect not only the respiratory system, but also the circulatory, nervous and digestive systems. The most common comorbidities in COVID-19 patients are hypertension, followed by diabetes, cardiovascular, and respiratory disease. Most conditions predisposing to SARS-CoV-2 infection are closely related to the metabolic syndrome. Obesity and chronic diseases, including liver disease, are associated with the induction of pro-inflammatory conditions and a reduction in immune response disorders, leading to the suspicion that these conditions may increase the susceptibility to SARS-CoV2 infection and the risk of complications. The definition of liver damage caused by COVID-19 has not yet been established. COVID-19 may contribute to both primary and secondary liver injury in people with pre-existing chronic disease and impaired liver reserves, leading to exacerbation of underlying disease, liver decompensation, or acute chronic liver failure. Therefore, many researchers have interpreted it as clinical or laboratory abnormalities in the course of the disease and treatment in patients with or without pre-existing liver disease. The research results available so far indicate that patients with liver disease require special attention in the event of COVID-19 infection.

show abstract

Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS)

Cited by 24 publications

References 32 publications

COVID-19 and liver disease

COVID-19 and liver disease

Outcomes of liver transplantation in recipients with previous coronavirus disease 2019 infection

Liver Injury in Patients with Coronavirus Disease 2019 (COVID-19)—A Narrative Review

Contact Info

Product

Resources

About